Positive safety and tolerability data were reported for OLX10212, a small interfering RNA technology, in patients with neovascular age-related macular degeneration, according to a press release from OliX Pharmaceuticals.
In the phase 1 study, 15 patients with wet AMD received OLX10212 at dose levels between 100 µg/eye/50 µL and 950 µg/eye/50 µL in one intravitreal injection.
There were no adverse effects related to OLX10212 during the 2-week dose-limiting toxicity evaluation period or the 22 weeks of clinical follow-up. Additionally, observed ophthalmic adverse events